UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

How will Trump's new tariffs impact US retailers? Why are Amazon engineers pressured to use AI more? What caused the recent retail buying spree rally? How might US-EU trade talks affect tariffs? Why is Nvidia's stock losing momentum ahead of earnings? What risks do Trump's trade policies pose to markets? How is AI changing job roles in tech companies? What led to layoffs at Microsoft amid AI adoption? How are oil prices reacting to US shale spending cuts?

UroGen Pharma Stock Receives Downgrade As Analyst Cites FDA Panel Setback For Key Bladder Cancer Drug

benzinga.com/general/biotech/25/05/45602598/urogen-pharma-stock-receives-downgrade-as-analyst-cites-fda-panel-setback-for-key-bladder-cancer-

HC Wainwright & Co. analyst Raghuram Selvaraju downgraded the rating on UroGen Pharma Ltd. (NASDAQ:URGN) from Buy to Neutral.
Selvaraju points out that the FDA’s Oncologic Drugs Advisory Committee voted 5-4 against the benefit-risk profile of UroGen’s investigational therapy UGN-102…

This story appeared on benzinga.com, 2025-05-25 18:16:05.